Substance / Medication

Melphalan hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

11 trials linked to this intervention

11
Total Trials
10
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy.
Piccardo Arnoldo, Treglia Giorgio, Fiz Francesco et al. · Eur J Nucl Med Mol Imaging · 2024
PMID: 37962616Meta-AnalysisFull text (PMC)
Efficacy and safety of proton beam therapy for rhabdomyosarcoma: a systematic review and meta-analysis.
Dong Meng, Wu Jianrong, Wu Renhua et al. · Radiat Oncol · 2023
PMID: 36805784Meta-AnalysisFull text (PMC)
Solution stability of Captisol-stabilized melphalan (Evomela) versus Propylene glycol-based melphalan hydrochloride injection.
Singh Ramsharan, Chen Jin, Miller Teresa et al. · Pharm Dev Technol · 2018
PMID: 27973975Observational
Melphalan hydrochloride for the treatment of multiple myeloma.
Esma Fabrizio, Salvini Marco, Troia Rossella et al. · Expert Opin Pharmacother · 2017
PMID: 28658983Review
Crystal Structure of Melphalan Hydrochloride and Its Association with Caffeine Improves Its Antineoplastic Action.
da Silva Juliana Pereira, Cristina da Silva Batista Carin, Schumacher Maria Lúcia et al. · ACS Omega · 2025
PMID: 40454050OtherFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Melphalan hydrochloride (substance)
SNOMED CT
426388000
UMLS CUI
C0771055

Clinical Data

This intervention maps to 5 entities in the Healos knowledge graph.

5
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
11
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.